Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization by Streptococcus pneumoniae--Alaska, 2008-2012 | Zendy

Prabhu Gounder | Zendy; Michael G. Bruce | Zendy; Dana Bruden | Zendy; Rosalyn Singleton | Zendy; Karen Rudolph | Zendy; Debby Hurlburt | Zendy; Thomas W. Hennessy | Zendy; Jay D. Wenger | Zendy

Open Access

Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization by Streptococcus pneumoniae--Alaska, 2008-2012

Author(s) -

Prabhu Gounder,

Michael G. Bruce,

Dana Bruden,

Rosalyn Singleton,

Karen Rudolph,

Debby Hurlburt,

Thomas W. Hennessy,

Jay D. Wenger

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit642

Subject(s) - streptococcus pneumoniae , pneumococcal conjugate vaccine , serotype , colonization , microbiology and biotechnology , pneumococcal infections , conjugate , pneumococcal disease , virology , conjugate vaccine , medicine , biology , antibiotics , mathematical analysis , mathematics

In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+). We conducted annual surveys from 2008 to 2012 to determine the effect of PCV13 on colonization by pneumococcal serotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research